WILMINGTON, Mass., Feb. 9, 2015 /PRNewswire/ -- Implant
Sciences Corporation (OTCQB:IMSC), a leading manufacturer of
explosives trace detection (ETD) and drugs trace detection
solutions for homeland security applications, announced today the
appointment of Robert Liscouski into
the newly created position of Executive Vice President. Mr.
Liscouski will manage and drive the company's business strategy,
business development and branding efforts. Mr. Liscouski will
report to Dr. William McGann, Chief
Executive Officer. Mr. Liscouski will continue to serve on the
Company's Board of Directors.
"I am excited to have this opportunity to help define the future
state of Implant Sciences and the implementation path for achieving
it. Implant Sciences has been a leader in developing innovative
capabilities, tools and solutions to counter the evolving terrorism
threats and help law enforcement in their efforts against the
illicit distribution of drugs and narcotics. Implant Sciences has
built a solid team and foundation of technology and capabilities
that enabled the company's QS-B220 system to achieve TSA
Certification and a contract with the TSA," stated Mr.
Liscouski.
Mr. Liscouski continued, "Based on those accomplishments and the
commitment of solid financial backing, we look forward to expanding
our sales into new markets across the
United States and internationally. In our modern world,
terrorists are constantly innovating and looking for new and
non-traditional ways to exploit our vulnerabilities. Improvised
Explosive Devices have become the terrorist's weapon of choice
throughout the world. Our innovation is focused on delivering the
best technology to counter these threats. This is our Company's
mission and I am proud to be taking on this role."
"Bob's experience and abilities to drive market strategy and
facilitate business growth, combined with his knowledge and
experience in Homeland Security, make him a key asset to our
Company," said Dr. William McGann,
CEO of Implant Sciences. "With his core strengths and leadership,
he will provide the essential added resources needed to further the
goals of Implant Sciences."
Mr. Liscouski is a recognized international security and
counterterrorism expert with more than 30 years of experience as a
senior government official, business leader, entrepreneur, special
agent and law enforcement officer. In 2003, he was appointed
by President George W. Bush as the
first Assistant Secretary for Infrastructure Protection at the U.S.
Department of Homeland Security. There he worked closely with
the White House and other federal agencies to design, develop and
implement the framework to protect the nation's critical physical
and cyber infrastructure following 9/11. Later Mr. Liscouski
founded a strategic advisory firm specializing in technology
start-ups in the homeland security area. Early in his career,
Mr. Liscouski worked in local law enforcement as a homicide and
undercover investigator and special agent for the Diplomatic
Security Service before joining a Fortune 100 company to develop
security systems to protect information technology and intellectual
property. He has been on the Implant Sciences Board of
Directors since 2009 and is a frequent contributor to CNN, Fox
News, and other business and security media.
About the QS-B220 Desktop Explosives and Drugs Trace
Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly
detect and identify trace amounts of a wide variety of military,
commercial, and homemade explosives as well as illicit drugs. With
significantly lower maintenance requirements than competing
systems, the QS-B220 can be deployed for a much lower total cost of
ownership than other approved products. Featuring a radioactive
material-free design, push-button maintenance and diagnostics, and
a patented inCalâ„¢ internal automatic calibration system, the
QS-B220 brings new levels of performance and convenience to desktop
trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The Company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 50 countries worldwide. Implant
Sciences is only the third manufacturer, and the sole
American-owned company, to currently have an ETD system named as a
Qualified Product by the US Transportation Security Administration.
The Company's ETDs have received approvals and certifications from
several international regulatory agencies including the TSA in the
U.S., ECAC in Europe, STAC in
France, the German Ministry of the
Interior, and the Ministry of Public Safety in China. For two consecutive years in 2013 and
2014 it received the GSN Homeland Security Award for "Best
Explosives Detection Solution". All Implant Sciences products are
recognized as Qualified Anti-Terrorism Technologies by the
Department of Homeland Security. For further details on the Company
and its products, please visit the Company's website at
www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking
statements," as that term is defined in the Private Securities
Litigation Reform Act of 1995. Such statements are based on
management's current expectations and are subject to risks and
uncertainties that could cause the Company's actual results to
differ materially from the forward-looking statements. Such risks
and uncertainties include, but are not limited to: the risk that
there is no guaranty that U.S. or foreign government and law
enforcement agencies or commercial consumers will purchase any of
our products or that any new products we may develop will be
accepted by the TSA or by such other governments, agencies or
consumers; economic, political and other risks associated with
international sales and operations could adversely affect our
sales; our business is subject to intense competition and rapid
technological change, and our success will depend on our ability to
develop and introduce new products; and other risks and
uncertainties described in our filings with the Securities and
Exchange Commission, including our most recent Forms 10-K, 10-Q and
8-K. Such statements are based on management's current expectations
and assumptions which could differ materially from the
forward-looking statements.
Implant Sciences Corporation
Company Contact:
Mike Turmelle, Director
978-752-1700 x 116
or
Investor Contact:
Laurel Moody
646-810-0608
Photo - http://photos.prnewswire.com/prnh/20150206/174103
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/implant-sciences-appoints-robert-liscouski-as-executive-vice-president-300032547.html
SOURCE Implant Sciences Corporation